Identification of module biomarkers from the dysregulated ceRNA-ceRNA interaction network in lung adenocarcinoma.

Competitive endogenous RNA (ceRNA) represents a novel layer of gene regulation that plays important roles in the physiology and development of diseases such as cancer and its dysregulation could contribute to cancer pathogenesis. Here, we have proposed a computational method to systematically identify genome-wide dysregulated ceRNA-ceRNA interactions by integrating microRNA regulation with expression profiles in cancer and normal tissues by RNA sequencing, as well as considering the details of how the behavior of ceRNAs has changed. These gain or loss dysregulations further assemble into a dysregulated ceRNA-ceRNA network; lncRNAs and pseudogenes are also considered. After applying the method to lung adenocarcinoma, we found that most dysregulations are connected together and formed a lung adenocarcinoma dysregulated ceRNA-ceRNA network (LDCCNet). Our analyses found that ceRNA pairs with gain regulations have consistent expression in cancer, otherwise for loss regulation, it is not necessary. Moreover, ceRNAs with more significant gain regulations (gain ceRNAs) undergo stronger regulation in cancer; thus their expression is more likely to decrease in cancer, while the expression of loss ceRNAs displays a rising trend. Additionally, we found that gain and loss ceRNAs as topological key nodes are implicated in the development of cancer. Finally, dysregulated ceRNA modules were identified, which are significantly enriched with known lung cancer microRNAs. We further found that several modules have the power as diagnostic biomarkers even in three independent datasets. For example, the module with lncRNA RP11-457M11.2 as a center is involved in the epithelial cell morphogenesis process and provides the average AUC values of 0.95. Our study about LDCCNet opens up the possibility of a new biological mechanism in cancer that could serve as a biomarker for diagnosis.

[1]  G. G. Stokes "J." , 1890, The New Yale Book of Quotations.

[2]  R. Stephenson A and V , 1962, The British journal of ophthalmology.

[3]  Miss A.O. Penney (b) , 1974, The New Yale Book of Quotations.

[4]  M. Ashburner,et al.  Gene Ontology: tool for the unification of biology , 2000, Nature Genetics.

[5]  Kevin Barraclough,et al.  I and i , 2001, BMJ : British Medical Journal.

[6]  Anton J. Enright,et al.  MicroRNA targets in Drosophila , 2003, Genome Biology.

[7]  Michael Thomas,et al.  MALAT-1, a novel noncoding RNA, and thymosin β4 predict metastasis and survival in early-stage non-small cell lung cancer , 2003, Oncogene.

[8]  D. Pe’er,et al.  Module networks: identifying regulatory modules and their condition-specific regulators from gene expression data , 2003, Nature Genetics.

[9]  Yanming Yang,et al.  TSGDB: a database system for tumor suppressor genes , 2003, Bioinform..

[10]  Thomas Lengauer,et al.  ROCR: visualizing classifier performance in R , 2005, Bioinform..

[11]  Alan F. Scott,et al.  Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders , 2004, Nucleic Acids Res..

[12]  Yuh-Shan Jou,et al.  A new tumor suppressor DnaJ-like heat shock protein, HLJ1, and survival of patients with non-small-cell lung carcinoma. , 2006, Journal of the National Cancer Institute.

[13]  Neil Genzlinger A. and Q , 2006 .

[14]  A. Pühler,et al.  Molecular systems biology , 2007 .

[15]  Delbert Dueck,et al.  Clustering by Passing Messages Between Data Points , 2007, Science.

[16]  Daniel A. Haber,et al.  Epidermal growth factor receptor mutations in lung cancer , 2007, Nature Reviews Cancer.

[17]  J. Delrow,et al.  Zbtb4 represses transcription of P21CIP1 and controls the cellular response to p53 activation , 2008, The EMBO journal.

[18]  Q. Cui,et al.  An Analysis of Human MicroRNA and Disease Associations , 2008, PloS one.

[19]  F. Slack,et al.  The let-7 microRNA reduces tumor growth in mouse models of lung cancer , 2008, Cell cycle.

[20]  Jiajie Zhang,et al.  MethyCancer: the database of human DNA methylation and cancer , 2007, Nucleic Acids Res..

[21]  Sung-Liang Yu,et al.  MicroRNA signature predicts survival and relapse in lung cancer. , 2008, Cancer cell.

[22]  Mihaela Campan,et al.  Identification of a panel of sensitive and specific DNA methylation markers for squamous cell lung cancer , 2008, Molecular Cancer.

[23]  D. Bartel,et al.  The impact of microRNAs on protein output , 2008, Nature.

[24]  Phillip A Sharp,et al.  Suppression of non-small cell lung tumor development by the let-7 microRNA family , 2008, Proceedings of the National Academy of Sciences.

[25]  D. Bartel MicroRNAs: Target Recognition and Regulatory Functions , 2009, Cell.

[26]  Lior Pachter,et al.  Sequence Analysis , 2020, Definitions.

[27]  D. Glavač,et al.  LATS2 tumour specific mutations and down-regulation of the gene in non-small cell carcinoma. , 2009, Lung cancer.

[28]  Yadong Wang,et al.  miR2Disease: a manually curated database for microRNA deregulation in human disease , 2008, Nucleic Acids Res..

[29]  Cole Trapnell,et al.  Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. , 2010, Nature biotechnology.

[30]  Q. Cui,et al.  Identification of high-quality cancer prognostic markers and metastasis network modules , 2010, Nature communications.

[31]  P. Pandolfi,et al.  A coding-independent function of gene and pseudogene mRNAs regulates tumour biology , 2010, Nature.

[32]  Jiayi Wang,et al.  CREB up-regulates long non-coding RNA, HULC expression through interaction with microRNA-372 in liver cancer , 2010, Nucleic acids research.

[33]  Mark D. Robinson,et al.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..

[34]  Nan Hu,et al.  A Gene Expression Signature from Peripheral Whole Blood for Stage I Lung Adenocarcinoma , 2011, Cancer Prevention Research.

[35]  P. Tsichlis,et al.  FGF-2 regulates cell proliferation, migration, and angiogenesis through an NDY1/KDM2B-miR-101-EZH2 pathway. , 2011, Molecular cell.

[36]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[37]  W. Fang,et al.  Gene expression profile changes and possible molecular subtypes in differentiated‐type nonkeratinizing nasopharyngeal carcinoma , 2011, International journal of cancer.

[38]  Xuerui Yang,et al.  An Extensive MicroRNA-Mediated Network of RNA-RNA Interactions Regulates Established Oncogenic Pathways in Glioblastoma , 2011, Cell.

[39]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[40]  P. Pandolfi,et al.  A ceRNA Hypothesis: The Rosetta Stone of a Hidden RNA Language? , 2011, Cell.

[41]  Yun Xiao,et al.  Prioritizing Candidate Disease miRNAs by Topological Features in the miRNA Target–Dysregulated Network: Case Study of Prostate Cancer , 2011, Molecular Cancer Therapeutics.

[42]  W. Marsden I and J , 2012 .

[43]  Min Pan,et al.  A miRNA-regulatory network explains how dysregulated miRNAs perturb oncogenic processes across diverse cancers , 2012, Genome research.

[44]  Bronwen L. Aken,et al.  GENCODE: The reference human genome annotation for The ENCODE Project , 2012, Genome research.

[45]  Yoo Jin Jung,et al.  The transcriptional landscape and mutational profile of lung adenocarcinoma , 2012, Genome research.

[46]  R. Zecchina,et al.  Integrated transcriptional and competitive endogenous RNA networks are cross-regulated in permissive molecular environments , 2013, Proceedings of the National Academy of Sciences.

[47]  Xing Chen,et al.  LncRNADisease: a database for long-non-coding RNA-associated diseases , 2012, Nucleic Acids Res..

[48]  Di Wu,et al.  miRCancer: a microRNA-cancer association database constructed by text mining on literature , 2013, Bioinform..

[49]  Bo Hu,et al.  Noncoding RNAs in cancer and cancer stem cells , 2013, Chinese journal of cancer.

[50]  Edwin Wang,et al.  Signaling network assessment of mutations and copy number variations predict breast cancer subtype-specific drug targets. , 2013, Cell reports.

[51]  Ming Cui,et al.  microRNAs and ceRNAs: RNA networks in pathogenesis of cancer. , 2013, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

[52]  Ting Wang,et al.  OncomiRDB: a database for the experimentally verified oncogenic and tumor-suppressive microRNAs , 2014, Bioinform..

[53]  Ana Kozomara,et al.  miRBase: annotating high confidence microRNAs using deep sequencing data , 2013, Nucleic Acids Res..

[54]  Julian Downward,et al.  Hmga2 functions as a competing endogenous RNA to promote lung cancer progression , 2013, Nature.

[55]  Yinghui Zhou,et al.  RTN4 3'-UTR insertion/deletion polymorphism and susceptibility to non-small cell lung cancer in Chinese Han population. , 2014, Asian Pacific journal of cancer prevention : APJCP.

[56]  Hui Zhou,et al.  starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein–RNA interaction networks from large-scale CLIP-Seq data , 2013, Nucleic Acids Res..

[57]  Feng Zhang,et al.  A novel biomarker Linc00974 interacting with KRT19 promotes proliferation and metastasis in hepatocellular carcinoma , 2014, Cell Death and Disease.

[58]  Xia Yang,et al.  Common dysregulation network in the human prefrontal cortex underlies two neurodegenerative diseases , 2014 .

[59]  Lorenzo Farina,et al.  Computational analysis identifies a sponge interaction network between long non-coding RNAs and messenger RNAs in human breast cancer , 2014, BMC Systems Biology.

[60]  Yu Cao,et al.  Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing , 2014, Science.

[61]  Z. Szallasi,et al.  Spatial and temporal diversity in genomic instability processes defines lung cancer evolution , 2014, Science.

[62]  Christopher R. Cabanski,et al.  Transcriptome sequencing reveals altered long intergenic non-coding RNAs in lung cancer , 2014, Genome Biology.

[63]  Yanchun Liang,et al.  3′UTR shortening identifies high-risk cancers with targeted dysregulation of the ceRNA network , 2014, Scientific Reports.

[64]  Steven J. M. Jones,et al.  Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.

[65]  E. Wang,et al.  Predictive genomics: a cancer hallmark network framework for predicting tumor clinical phenotypes using genome sequencing data. , 2014, Seminars in cancer biology.

[66]  P. Economopoulou,et al.  Beyond EGFR and ALK inhibition: unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer. , 2015, Cancer treatment reviews.

[67]  Aaas News,et al.  Book Reviews , 1893, Buffalo Medical and Surgical Journal.